目的 研究胆管癌miR-551b表达变化的临床意义,并采用生物信息学方法分析其靶基因。方法 选择2014-10至2018-10在武警安徽总队医院行胆管癌根治术的78例患者作为胆管癌组,并选择同期因胆管结石行Roux-en-Y胆肠吻合术的40例患者作为对照组,检测胆管癌组织和正常胆管组织中miR-551及细胞周期素D1(cyclinD1)的表达量,随访胆管癌患者的总生存期(OS)。结果 胆管癌组织中miR-551b的表达量低于正常胆管组织且术前血清CA19-9升高、术前血清CEA升高、TNM Ⅲ期、低未分化、微血管侵犯患者胆囊癌组织中miR-551b的表达量明显低于术前血清CA19-9正常、术前血清CEA正常,TNM Ⅰ-Ⅱ期、中高分化、无微血管侵犯的患者;与miR-551b高表达的胆管癌患者比较,miR-551b低表达的胆管癌患者的总生存期明显缩短;miR-551b靶向cyclinD1基因mRNA 3'UTR的第1456-1462碱基、1479-1486碱基,胆管癌组织中cyclinD1的表达水平明显高于正常胆管组织且与miR-551b 的表达具有负相关关系;术前CA19-9、TNM分期、微血管侵犯、miR-551b及cyclinD1表达是胆管癌患者总生存期的影响因素。结论 胆管癌中miR-551表达减少与病理特征恶化、总生存期缩短相关,靶向cyclinD1是miR-551参与胆管癌发生发展的可能机制。
Abstract
Objective To study the clinical significance of miR-551b expressions in cholangiocarcinoma and analyze the target gene of mir-551b by bioinformatics.Methods Seventy-eight patients with cholangiocarcinoma who underwent radical resection in our hospital between October 2014 and October 2018 were selected as the cholangiocarcinoma group while another 40 patients who underwent Roux-en-Y cholangiojejunostomy due to bile duct stones were selected as the control group.The expressions of miR-551 and cyclin D1 in cholangiocarcinoma and normal bile duct tissues were calculated and the overall survival (OS) of patients with cholangiocarcinoma was followed up.Results The expression of miR-551b in cholangiocarcinoma tissues was lower than that in normal bile duct tissues.The expression of miR-551b in cholangiocarcinoma tissues of patients with increased preoperative serum CA19-9 and CEA,in TNM stage Ⅲ,or with low-undifferentiated and microvascular invasion were significantly lower than that of patients with normal preoperative serum CA19-9 and CEA,in TNM stageⅠ-Ⅱ,or with medium-high differentiation and non-microvascular invasion.Compared with cholangiocarcinoma patients with high miR-551b expressions,the overall survival of patients with low expressions of miR-551b was significantly shortened.miR-551b targeted 1456-1462 and 1479-1486 bases of mRNA 3′UTR of CyclinD1 gene,and the expression level of CyclinD1 in cholangiocarcinoma was significantly higher than that in the normal bile duct and negatively correlated with the expression of miR-551b.Preoperative CA19-9,TNM stage,microvascular invasion,and expressions of miR-551b and cyclinD1 were factors that influenced the overall survival of patients with cholangiocarcinoma.Conclusions The decrease of miR-551 expression in cholangiocarcinoma is related to the deterioration of pathological features and the shortening of total survival time.Targeting CyclinD1 is a possible mechanism by which miR-551 is involved in the occurrence and development of cholangiocarcinoma.
关键词
胆管癌 /
miR-551b /
cyclinD1 /
靶基因 /
生物信息学
Key words
cholangiocarcinoma /
mir-551b /
cyclinD1 /
target gene /
bioinformatics
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Liu H,Cen X,Suo T,et al.Trends and hospital variations in surgical outcomes for cholangiocarcinoma in New York State[J].World J Surg,2017,41(2):525-537.
[2] Chang W W,Hsiao P K,Qin L,et al.Treatment outcomes for unresectable intrahepatic cholangiocarcinoma:Nationwide,population-based,cohort study based on propensity score matching with the Mahalanobis metric[J].Radiother Oncol,2018,129(2):284-292.
[3] Zhou M,Zhu Y,Hou R,et al.Identification of candidate genes for the diagnosis and treatment of cholangiocarcinoma using a bioinformatics approach [J].Oncol Lett,2019,18(5):5459-5467.
[4] Wang J,Xu M X,Wang L Q,et al.Correlation between KRAS gene mutations and linicopathological features of patients with intrahepatic cholangiocarcinoma[J].J Biol Regul Homeost Agents,2019,33(5):1551-1557.
[5] Li S,Chai Y,Ding Y,et al.CHD1L is associated with poor survival and promotes the proliferation and metastasis of intrahepatic cholangiocarcinoma[J].Oncol Rep,2019,42(2):657-669.
[6] Xu L,Wang L,Zhou L,et al.The SIRT2/cMYC pathway inhibits peroxidation-related apoptosis in cholangiocarcinoma through metabolic reprogramming [J].Neoplasia,2019,21(5):429-441.
[7] Chang W,Wang Y,Li W,et al.MicroRNA-551b-3p inhibits tumour growth of human cholangiocarcinoma by targeting Cyclin D1[J].J Cell Mol Med,2019,23(8):4945-4954.
[8] Adeva J,Sangro B,Salati M,et al.Medical treatment for cholangiocarcinoma[J].Liver Int,2019,39(Suppl 1):123-142.
[9] Lin P,Zhong X Z,Wang X D,et al.Survival analysis of genome-wide profiles coupled with connectivity map database mining to identify potential therapeutic targets for cholangiocarcinoma[J].Oncol Rep,2018,40(6):3189-3198.
[10] 宗 源,周 军,沈 琳.晚期胆管癌的药物治疗现状[J].中华临床医师杂志(电子版),2019,13(3):214-220.
[11] Lukic A D I,Properzio M,Carico E,et al.MicroRNA-551b expression profile in low and high-grade cervical intraepithelial neoplasia [J].Eur Rev Med Pharmacol Sci,2018,22(14):4448-4457.
[12] Wang Y,Fan X,Xu F,et al.Expression of miR-551b and its effect on apoptosis in human gastric carcinoma[J].Int J Clin Exp Pathol,2018,11(5):2912-2919.
[13] Sun H Y,Qu Z C,Liu D M,et al.Decreased expression of miR-551b predicts poor prognosis and promotes tumorigenesis by targeting PTP4A3 in human colorectal cancer [J].Eur Rev Med Pharmacol Sci,2019,23(13):5741-5751.
[14] Sittithumcharee G,Suppramote O,Vaeteewoottacharn K,et al.Dependency of cholangiocarcinoma on cyclin D-dependent kinase activity[J].Hepatology,2019,70(5):1614-1630.
[15] 田立斌,张海光,鲁 鑫,等.淋巴增强因子1及细胞周期蛋白D1在肝门部胆管癌中的表达及其临床意义[J].临床与病理杂志,2018,38(5):942-946.
PDF(950 KB)
